cphi-onlineFebruary 14, 2017
Tag: Jazz Pharmaceuticals , patient
JZP-110 is a selective dopamine and norepinephrine reuptake inhibitor.
Jazz Pharmaceuticals has announced that the first patient has been enrolled in a Phase II clinical study evaluating JZP-110, a selective dopamine and norepinephrine reuptake inhibitor, as a potential treatment for excessive sleepiness (ES) in adult patients with Parkinson's disease. The clinical study will be conducted across approximately 15 centres in the US.
"Excessive sleepiness is a debilitating symptom of Parkinson's disease, and we are interested in determining whether the wake-promoting effects of JZP-110 could be beneficial in this patient population," said Karen Smith, global head of research and development and chief medical officer of Jazz Pharmaceuticals. "The initiation of this study is another step forward in our development program for JZP-110 and our efforts to develop new treatment options for people with sleep disorders."
The Phase II study is a double-blind, placebo-controlled, randomized, multicenter, crossover study evaluating the safety, efficacy and pharmacokinetics of JZP-110 in adult patients with Parkinson's disease and ES. The study is expected to enrol approximately 50 patients.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: